开源日报 每天推荐一个 GitHub 优质开源项目和一篇精选英文科技或编程文章原文,坚持阅读《开源日报》,保持每日学习的好习惯。
今日推荐开源项目:《spring-boot-demo》
今日推荐英文原文:《FDA panel backs Pfizer’s COVID-19 vaccine for emergency use in US》
开源日报第977期:《spring-boot-demo》
今日推荐开源项目:《spring-boot-demo》传送门:项目链接
推荐理由:spring boot demo是一个用来深度学习并实战spring boot的项目,目前总共包含一个66集成demo,已经完成54个。 该项目已成功集成驱动器(监控),admin(可视化监控),logback(日志),aopLog(通过AOP记录web请求日志),统一异常处理(json级别和页面级别),freemarker(模板引擎),thymeleaf(模板引擎),Beetl(模板引擎),Enjoy(模板引擎),JdbcTemplate(通用JDBC操作数据库),JPA(强大的ORM框架) ,mybatis(强大的ORM框架),通用Mapper(快速操作Mybatis),PageHelper (),mybatis 通用的Mybatis分页插件-plus(快速操作Mybatis),BeetlSQL(强大的ORM框架),upload(本地文件上传和七牛云文件上传),redis(缓存),ehcache(缓存),email(发送各种类型邮件),task(基础定时任务),quartz(动态管理定时任务),xxl- job(分布式定时任务),swagger(API接口管理测试),security(基于RBAC的动态权限认证),SpringSession(Session共享),Zookeeper(结合AOP实现分布式锁),RabbitMQ(消息队列),Kafka(消息队列),websocket(服务端推送监控服务器运行信息),socket.io(聊天室),ureport2(中国式报表),打包成war文件,集成ElasticSearch(基本操作和高级查询) ,Async(异步任务),IntegratedDubbo(采用官方的starter),MongoDB的(文档数据库),Neo4j的(图数据库),搬运工(容器化), ,JPA多数据源,Mybatis多数据源,GrayLog(代码生成器 日志收集),JustAuth(),LDAP(第三方登录 增删改查),,动态添加/切换数据源单机限流(AOP + Guava RateLimiter),分布式限流(AOP + Redis + Lua),ElasticSearch 7.x的(使用官方 Rest High Level Client), HTTPS,Flyway(数据库初始化)。
今日推荐英文原文:《FDA panel backs Pfizer’s COVID-19 vaccine for emergency use in US》作者:Abrar Al-Heeti
原文链接:https://www.cnet.com/news/fda-panel-backs-pfizers-covid-19-vaccine-for-emergency-use-in-us/
推荐理由:疫情仍在美国肆虐, 疫苗的开发进度也是全球范围内的焦点. 美国食品和药物管理局的一个咨询小组周四正式提出辉瑞公司在美国的疫苗具有紧急使用授权, 若得到授权该疫苗可在几天之内在美国推出。

FDA panel backs Pfizer’s COVID-19 vaccine for emergency use in US

A US Food and Drug Administration advisory panel on Thursday formally recommended emergency use authorization for Pfizer’s COVID-19 vaccine in the United States. If the FDA chooses to accept the recommendation, the vaccine could be rolled out in the US within days.

Pharmaceutical giant Pfizer, which developed the vaccine with German partner BioNTech, said last month that the vaccine demonstrated 95% effectiveness in clinical trials. The companies applied for emergency use authorization from the FDA in late November. A review published by the FDA on Tuesday confirmed that the vaccine meets the standard for emergency use authorization.

The recommendation came out of a daylong FDA meeting Thursday. An independent panel of experts, known as the Vaccines and Related Biological Products Advisory Committee, has been discussing the Pfizer vaccine in detail.

Pfizer and BioNTech have conducted human trials on more than 43,000 people in six countries. They initially reported more than 90% effectiveness for the vaccine, before a final data analysis found that it was 95% effective in preventing COVID-19, with no serious side effects.

The Pfizer vaccine — as well as another from US drug developer Moderna, which is said to be 94% effective — is an experimental RNA vaccine. It uses synthetic messenger RNA, or mRNA, a molecule that tells cells how to build proteins. It can then trick cells into producing proteins typically found in SARS-CoV-2, the virus that causes COVID-19, which in turn can then stimulate the immune system — without making patients sick — to protect against infection. Moderna has also applied for FDA emergency approval for its coronavirus vaccine.

Given that there are more than 330 million people in the US, not everyone will be able to get the vaccine right away. Health care workers will be prioritized, as well as people at higher risk of infection due to age, underlying conditions or profession.

Administering the coronavirus vaccine

On Tuesday, the UK became the first country to start administering the Pfizer COVID-19 vaccine, following clinical approval. The first person to receive the vaccine outside of a clinical trial was 90-year-old Margaret Keenan, who was given the first of two injections needed. Four million people in the UK are expected to begin the process by the end of December. Canada approved Pfizer’s vaccine on Wednesday.

There are several dozen coronavirus vaccines in various stages of clinical trials, with some almost ready to be submitted for potential authorization. Most experts say we’ll have many more ready to distribute by early 2021.

In a panel earlier this week, Dr. Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said the sooner the United States can convince the overwhelming majority of people to get vaccinated, the sooner things will be “close to normal.”

The first cases of COVID-19 were reported in China a year ago this month. By March, a pandemic was in full force. According to the Johns Hopkins coronavirus dashboard, more than 69 million cases have been confirmed worldwide and nearly 1.6 million people have died of COVID-19 as of Thursday.
下载开源日报APP:https://openingsource.org/2579/
加入我们:https://openingsource.org/about/join/
关注我们:https://openingsource.org/about/love/